XenoPort's CEO Presents At Morgan Stanley Healthcare Conference (Transcript)

XenoPort, Inc. (XNPT)

Morgan Stanley Healthcare Conference

September 11, 2012 03:00 pm ET

Executives

Ron Barrett - Chief Executive Officer and Director

Analysts

David Friedman - Morgan Stanley

Presentation

David Friedman - Morgan Stanley

All right, so I think we'll get started. Thanks everyone for joining us and I'm David Friedman, Biotech Analyst here. In terms of our disclosure statement, you can find research disclosures at morganstanley.com/researchdisclosures, and I am joined by Ron Barrett here, CEO of XenoPort, and one of the best performing stocks in all of small and midcap biotech this year, so a lot going on and I would to go into it, so maybe if you can just a one or two-minute overview of the company, and then we can just jump right into the program.

Ron Barrett

Sure. Thanks for the invitation to speak today and I am going to be making forward-looking statements and you should consult SEC documents with information with regard to risks and uncertainties of our business.

XenoPort, it's a very interesting time for the company. We have a series of products and product candidates that are in different stages and walk through them one at a time. Our gabapentin enacarbil is an approved product in the U.S. and Japan, and Horizant is the trade name in the U.S. and Regnite in Japan.

It's approved for the treatment of moderate-to-severe primary RLS in the U.S. and Japan, and also for postherpetic neuralgia in the U.S. we are partnered with GSK in the U.S. and Astellas in Japan, and I would say that I really don't have an update on Horizant's. It launched last July. The sales have been blockbuster and it's been very frustrating for us as a company, and as you undoubtedly know we are in litigations with GSK, I don't really have any update on the litigation today.

If you liked this article you might like

Ardelyx Has Big Potential

Ardelyx Has Big Potential

Biotech M&A Waking Up After Long Nap

Biotech M&A Waking Up After Long Nap

Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium

Here's Why XenoPort (XNPT) Stock is Continuing to Surge Today

Trending Tickers: XNPT, OLED, MON, TPUB

Trending Tickers: XNPT, OLED, MON, TPUB